Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab plus pomalidomide/dexamethasone vs pomalidomide/dexamethasone in relapsed and refractory multiple myeloma
jRCT2080223190Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of elotuzumab in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival (PFS) and Overall response rate (ORR). Started May 2016; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080223190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223190.